PTEN is a frequently mutated tumor suppressor gene that opposes the PI3K/AKT pathway through dephosphorylation of phosphoinositide-3,4,5-triphosphate. Recently, nuclear compartmentalization of PTEN was found as a key component of its tumor-suppressive activity; however its nuclear function remains poorly defined. Here we show that nuclear PTEN interacts with APC/C, promotes APC/C association with CDH1, and thereby enhances the tumor-suppressive activity of the APC-CDH1 complex. We find that nuclear exclusion but not phosphatase inactivation of PTEN impairs APC-CDH1. This nuclear function of PTEN provides a straightforward mechanistic explanation for the fail-safe cellular senescence response elicited by acute PTEN loss and the tumor-suppressive activity of catalytically inactive PTEN. Importantly, we demonstrate that PTEN mutant and PTEN null states are not synonymous as they are differentially sensitive to pharmacological inhibition of APC-CDH1 targets such as PLK1 and Aurora kinases. This finding identifies a strategy for cancer patient stratification and, thus, optimization of targeted therapies.
INTRODUCTION
PTEN (phosphatase and tensin homolog) is among the most frequently lost or mutated tumor suppressors, with a frequency of monoallelic mutations estimated at 50%-80% in endometrial carcinoma, glioblastoma, and prostate cancer and at 30%-50% in breast, colon, and lung tumors (Cairns et al., 1997; Feilotter et al., 1998; Gray et al., 1998; Li and Sun, 1997; Steck et al., 1997) . Complete loss of PTEN is observed at highest frequencies in endometrial cancer and glioblastoma and is generally associated with metastatic cancers (Ali et al., 1999; Salmena et al., 2008) . Moreover, germline mutations of PTEN have been identified in cancer-susceptibility syndromes such as Cowden syndrome (Di Cristofano et al., 1998; Eng, 2003) .
PTEN can dephosphorylate phosphoinositide-3,4,5-triphosphate (PIP 3 ), a potent activator of AKT (Maehama and Dixon, 1998) . Loss of PTEN function leads to derepression of the PI3K/AKT pathway, which stimulates cell growth and survival (Stambolic et al., 1998; Sun et al., 1999) . However, emerging evidence suggests that PTEN also has PI3K/AKT-independent functions . Furthermore, cells harboring phosphatase-inactive PTEN mutants retain residual tumorsuppressive activity, leading to the hypothesis that PTEN exerts functions that are independent of its phosphatase activity (Blanco-Aparicio et al., 2007; Georgescu et al., 2000; Gildea et al., 2004; Koul et al., 2002; Maier et al., 1999) .
Early studies proposed that PTEN was exclusively cytoplasmic. However, recent reports clearly demonstrate that nuclear PTEN has important tumor-suppressive function (Fridberg et al., 2007; Perren et al., 2000; Whiteman et al., 2002; Zhou et al., 2002) . Mechanistically, we have reported that ubiquitination of PTEN regulates its nuclear compartmentalization (Song et al., 2008; Trotman et al., 2007) . However, the tumorsuppressive functions of PTEN within the nucleus still remain poorly defined.
Cell-cycle progression is controlled by ubiquitination-mediated proteolysis of cell-cycle machinery. The two major E3 ubiquitin ligases controlling this process are SCF (Skp1/Cullin/F-box protein complex) and APC/C (anaphase-promoting complex/ cyclosome). SCF mainly controls target protein levels during S phase, whereas APC/C is thought to be active from mitosis to late G1 (Cardozo and Pagano, 2004; Peters, 2006) . APC/C contains at least 11 different structural subunits, and its activity is controlled through the binding of CDC20 and CDH1, which recognize and recruit specific substrates. CDC20 is active in early mitosis whereas CDH1 activity is restricted to late mitosis and G1 (Pines, 2006; Sullivan and Morgan, 2007) . Specific APC/C substrates include mitotic cyclins (Cyclins A and B), mitotic kinases (Aurora kinases, PLK1, Nek2A), proteins involved in chromosome segregation (Securin, Sgo1), DNA replication proteins (Geminin, Cdc6), an F-box protein (SKP2), and transcription factors (Ets2, FoxM1) (Manchado et al., 2010; Wasch et al., 2010) .
Of importance, APC-CDH1 substrates, such as Cyclin A, PLK1, Aurora A, CDC20, or SKP2, are overexpressed in human tumors and are associated with chromosomal instability and poor prognosis (Carter et al., 2006) . In mice, Cdh1 heterozygosity results in the development of epithelial tumors, suggesting that CDH1 may be a haploinsufficient tumor suppressor (Garcia-Higuera et al., 2008) . Downregulation of CDH1 has been reported in many cancers, including those of prostate, ovary, liver, and brain, and during the malignant progression of a B-lymphoma cell line (Bassermann et al., 2008; Wang et al., 2000) . Therefore, inactivation of APC-CDH1 in cancer may lead to unchecked accumulation of its targets with profound consequences for cell-cycle and genomic stability.
In this study, we demonstrate that nuclear PTEN directly enhances the activity of APC/C by promoting its association with CDH1. Conversely, PTEN loss impairs the activity of the APC-CDH1 tumor-suppressive complex. Critically, PTEN activates APC-CDH1 in a phosphatase-independent manner, an observation that has important implications for cancer therapy.
RESULTS
Nuclear PTEN Interacts with APC/C In order to identify novel tumor-suppressive pathways regulated by PTEN, we immunoprecipitated exogenous Myctagged PTEN from the nuclear extracts of PTEN-deficient PC3 cells and identified interacting proteins by mass spectrometry ( Figure 1A and Figure S1A Figure 1B ) and observed that the binding was restricted to the nucleus ( Figures  S1B and S1C) . Notably, an in vitro binding assay revealed that the interaction of PTEN with APC3 is restricted to the COOH terminus of PTEN, indicating that the N-terminal phosphatase domain is dispensable for this interaction ( Figure 1C ). Critically, PTEN immunoprecipitation complexes displayed ubiquitinating ability toward the well-established APC/C target Cyclin B ( Figure 1D ). We next assessed the functional relevance of this physical interaction. To test whether PTEN directly affects the levels of APC/C targets, we developed a model system in which we could dissociate the consequences of acute PTEN induction from the ensuing cell-cycle effects. For this we used a Tetracyclin-inducible (Tet-on)-PTEN cellular system in asynchronously growing PC3 cells (Rubin et al., 1991) . In this cellular system, acute PTEN induction precedes any sizable effects on cell-cycle distribution for at least 12 hr ( Figure 1E ). By contrast, in this timeframe PTEN induction led to a marked and rapid proteasome-dependent downregulation of APC/C targets. This was reverted by MG132 treatment, at time points much earlier than any detectable effect on cell-cycle distribution ( Figure 1E ). Moreover, we found that APC/CDH1 target levels were increased in vivo in Pten null prostates at time points where the incidence of prostate intraepithelial neoplasia (PIN) and the increase of cell proliferation are low ( Figure 1F , Figure S1D , and data not shown). Similarly, PTEN silencing in DU145 cells led to the upregulation of the APC/C targets, Cyclin A2, Geminin, PLK1, Aurora A, and CDC20, whereas overexpression of PTEN in PTEN-deficient LNCaP and PC3 cells reduced APC/C target levels concomitant with G1 cell-cycle arrest (Figures S1E and S1F).
Nuclear PTEN Enhances the Activity of APC-CDH1 Our data show that PTEN interacts with components of the APC/C complex and PTEN status alters the level of APC/C complex target proteins. Thus, we hypothesized that PTEN can regulate the ubiquitin ligase activity of APC/C. Indeed, in vitro APC/C ubiquitin ligase assays revealed that Cyclin B ubiquitination by APC/C was increased in a dose-dependent manner by recombinant PTEN protein in the presence of CDH1 (Figure 2A ). By contrast, the ubiquitin ligase activity of APC/C was reduced in Pten À/À mouse embryonic fibroblasts (MEFs) compared to wild-type cells ( Figure 2B ). Remarkably, nuclear but not cytoplasmic PTEN immunoprecipitates were capable of ubiquitinating Cyclin B ( Figure 2C ). Next, we sought to ascertain the mechanism by which PTEN regulates APC/C function. APC/C activation occurs upon the association with two different adaptor proteins, CDC20 and CDH1 (Cardozo and Pagano, 2004; Peters, 2006) . Whereas CDC20 activates APC/C in early mitosis, APC-CDH1 is active in late mitosis and during G1 (Pines, 2006; Sullivan and Morgan, 2007) . In vitro Cyclin B ubiquitination assays revealed that the ubiquitin ligase activity of PTEN immunoprecipitates in interphase was higher than in mitosis ( Figure S1G ). We therefore examined whether PTEN regulates the formation of the APC-CDH1 complex. In vivo, reintroduction of PTEN into PC3 cells increased the association between APC3 and CDH1 (Figure 2D, top panel) , whereas PTEN knockdown in DU145 dramatically reduced the coimmunoprecipitation of APC3 and CDH1 ( Figure 2D, bottom panel) . In vitro binding assay revealed that PTEN favors the assembly between APC3 and CDH1 in a dose-dependent manner ( Figure 2E ). Taken together, these results suggest that PTEN promotes the association between APC and CDH1, thereby enhancing the activity of APC-CDH1.
Nuclear Exclusion of PTEN Impairs Activation of APC-CDH1 Despite the increasing number of studies emphasizing the importance of nuclear PTEN as a tumor suppressor (Planchon et al., 2008; Salmena et al., 2008) , how nuclear PTEN exerts its tumor-suppressive activity remains unclear. We have demonstrated that PTEN monoubiquitination at lysines 13 and 289 is essential for its nuclear localization and tumor-suppressive function, and conversely, deubiquitination of PTEN by HAUSP renders PTEN predominantly cytoplasmic (Song et al., 2008; Trotman et al., 2007 ). Therefore, we tested whether a nuclearexcluded PTEN K13,289E mutant ( Figure 3A ) could still regulate APC-CDH1. In vivo ubiquitination assay showed that, unlike wild-type PTEN, nuclear-excluded PTEN K13,289E was unable to promote the Cyclin B ubiquitination and to reduce the level of APC-CDH1 targets despite antagonizing AKT activation (Figure 3B and Figure S2A ). Importantly, coimmunoprecipitation analysis revealed that PTEN K13,289E mutant failed to interact with APC3 ( Figure 3C ). Because both PTEN and APC-CDH1 are known negative regulators of cell proliferation Wasch et al., 2010) , we next examined the effects of nuclear exclusion of PTEN on cell growth. BrdU incorporation analysis revealed that nuclear-excluded PTEN K13,289E mutant was ineffective in suppressing S phase entry after release from nocodazole block, whereas PTEN WT significantly delayed the G1-S transition accompanied with a reduction in the level of APC-CDH1 targets ( Figure 3D and Figure S2B ). This observation is of critical relevance as it allowed us to uncouple the effect of PTEN on Akt and APC-CDH1 toward cell-cycle regulation. In line with this notion, PTEN WT but not PTEN K13,289E overexpression led to a downregulation of CDK2 activity due to reduction in the level of Cyclin A 2 rather than Cyclin E at the G1-S transition, suggesting that nuclear PTEN might regulate the G1-S transition through reduction in the level of Cyclin A 2 , an APC-CDH1 target ( Figure 3E ). We also ascertained whether the delay in S phase entry by PTEN could be due to failure to be released from the nocodazole block or to exit from mitosis. PTEN K13,289E as well as PTEN WT overexpression had little impact on mitotic exit, as measured by the positivity of phospho-histone H3 ( Figures  S2C and S2D ). In addition, PTEN WT -or PTEN K13,289E -expressing PC3 cells exhibited similar proportions of cells in mitosis upon nocodazole block, suggesting that PTEN might not be involved in spindle checkpoint (SAC) as well. Taken together, these results suggest that nuclear localization of PTEN is necessary for activation of APC-CDH1, thereby regulating cell-cycle progression.
Growth-Suppressive Activity of PTEN Requires APC-CDH1 Next, we examined the requirement of APC-CDH1 function in PTEN-mediated cell growth suppression. The effects of PTEN on cell-cycle distribution as well as APC-CDH1 target modulation were completely abrogated by depletion of APC3 or CDH1 (Figures 4A and 4B) . We then evaluated the contribution of APC-CDH1 to the growth-suppressive function of PTEN by using wild-type and Cdh1 À/À MEFs (among which the phosphatase activity of endogenous Pten was indistinguishable; Figure 4C ). Strikingly, whereas PTEN overexpression induced a growth inhibition in immortalized Cdh1 +/+ cells (or in Cdh1 À/À MEFs complemented with human CDH1), Cdh1 À/À cells were refractory to this effect of PTEN overexpression ( Figure 4D , top panel). Consistent with these data, overexpression of PTEN was accompanied by the downregulation of Cyclin A 2 -associated CDK2 activity as well as other APC-CDH1 targets in Cdh1 +/+ (or in Cdh1
, bottom panel and Figure S3A ). Conversely, the increase in proliferation and elevation of the level of APC-CDH1 targets induced by Pten silencing was abrogated in the absence of Cdh1 ( Figure 4E and Figure S3B ). Taken together, these results suggest that the growth-suppressive activity of PTEN is, at least in part, mediated by APC-CDH1.
PTEN-Loss-Induced Cellular Senescence Involves APC-CDH1
Reduction of cellular levels of PTEN or CDH1 results in the decrease of their respective tumor-suppressive activity (Di Cristofano et al., 1998; Garcia-Higuera et al., 2008) . However, acute and complete loss of both Pten and Cdh1 leads to a fail-safe cellular senescence response; this phenomenon has been shown to profoundly suppress tumor progression upon Pten loss (Chen et al., 2005; Li et al., 2008) . We therefore hypothesized that Pten-loss-induced senescence could be in part mediated by a reduction of Cdh1 activity toward mediators of cellular senescence. In order to test this hypothesis, we overexpressed CDH1 concomitantly with the acute inactivation of Pten in Pten
MEFs. Strikingly, overexpression of CDH1 counteracted the senescence response ( Figures 5A and 5B) . Importantly, overexpression of CDH1 specifically prevented the increase of p16 mRNA and protein levels, but not those of Arf or p53 ( Figures  5C and 5D and Figure S4A ). Conversely, complete concomitant inactivation of Cdh1 and Pten in MEFs dramatically increased the distinctive morphology of senescent cells (flattened large cells; data not shown) and the positivity for senescence-associated b-galactosidase (SA-b-Gal), a hallmark of senescent cells ( Figure 5E and Figure S4B ). Consistent with these data, complete loss of Cdh1 upon Pten loss led to reduced proliferation compared to Pten loss alone, as measured by growth curves and BrdU incorporation analysis ( Figure 5F ). Of note, the senescence response elicited upon acute loss of Pten was accompanied by elevation of p19 ARF (Arf)/p53/p21 as well as p16 INK4A (p16) (Figures 5C and 5G) . We have previously reported that senescence elicited by acute loss of Pten is accompanied by the acti- Figure S2 . p value was determined by Student's t test (*p < 0.01).
vation of the p53 pathway (Chen et al., 2005) . Interestingly, complete loss of Cdh1 and Pten led to a dramatic accumulation of p16, whereas Arf or p53/p21 was not affected compared to Pten loss alone. Critically, silencing of p16 prevented Pten-loss-induced senescence without affecting the p53 axis ( Figures S4C-S4E ). In line with previous reports from our lab, p19 silencing also reduced cellular senescence in Pten null MEFs without affecting p53 ( Figures S4C-S4E) (Chen et al., 2009 ). As Ets2 has been shown to selectively regulate p16, but not Arf transcription (Huot et al., 2002; Ohtani et al., 2001) , we analyzed Ets2 levels in Pten null cells to determine whether an increase in Ets2 could account for the enhanced expression of p16. Indeed, Ets2 protein but not mRNA level was markedly upregulated by acute loss of Pten (Figures 5C and 5G and Figure S4F ). Of interest, consistent with the notion that APC-CDH1 regulates the ubiquitination-mediated degradation of Ets2 ( Figure S4G ) (Li et al., 2008) , PTEN promoted the ubiquitination of wild-type but not destruction box mutated (DBM) Ets2 ( Figure 5H ). To determine the direct role of the Ets2/p16 pathway on active senescence in Pten null cells, we overexpressed or silenced Ets2 upon acute Pten loss. Overexpression of DBM Ets2 significantly promoted the senescence response by Pten loss even in the presence of CDH1 ( Figure 5I ), whereas silencing of Ets2 dramatically reduced senescence and the transcriptional induction of p16 ( Figures S4H and S4I) . Collectively, these data provide a compelling mechanism for the senescence response elicited by Pten loss through parallel CDH1/Ets2/p16 and Arf or p53/p21. PTEN Regulates APC-CDH1 Independently of Its Phosphatase Activity PTEN opposes the PI3K/AKT signaling pathway by catalyzing the dephosphorylation of PIP3 (Maehama and Dixon, 1998) . Loss of PTEN leads to the activation of the PI3K/AKT cascade and stimulates cell growth and survival (Stambolic et al., 1998; Sun et al., 1999) . Nevertheless, cells harboring phosphataseinactive PTEN mutants are phenotypically distinct from cells lacking PTEN protein, suggesting that PTEN exerts functions that are independent of its phosphatase activity (Blanco-Aparicio et al., 2007; Georgescu et al., 2000; Gildea et al., 2004; Maier et al., 1999; Okumura et al., 2005) . In order to examine the contribution of the phosphatase activity of PTEN in the regulation of APC-CDH1, we first complemented PTEN null PC3 cells, with either wild-type or phosphatase-inactive PTEN (C124S or G129E) ( Figure 6A ). The levels of several canonical APC-CDH1 Figure 4 . Growth Suppression by PTEN Relies on APC-CDH1 Function (A and B) PC3 cells cotransfected with empty vector or HA-PTEN and Renilla luciferase siRNA (siControl), two independent APC3 siRNAs (siAPC3-1 and -2) (A), or CDH1 siRNAs (siCDH1-1 and -2) (B) were subjected to immunoblotting (top) and flow cytometric analysis to measure cell-cycle distribution (bottom). The relative immunoreactivity of each protein was quantified by normalizing with Hsp90. (C) diC 8 -PtdIns(3,4,5)P 3 (40 mM) was incubated with and without (control) the immunopurified Pten (1 mg) at 37 C for 30 min. targets were reduced upon expression of PTEN(C124S) or PTEN(G129E) phosphatase-inactive mutants in this system ( Figure S5A ). Consistently, expression of phosphatase-inactive PTEN(C124S) in PC3 cells resulted in a delayed entry into S phase, a phenotype similar to that in wild-type PTEN-expressing PC3 cells or PTENproficient DU145 cells, implying that PTEN regulates the G1-S transition independent of its phosphatase activity ( Figure 6B and Figures S5B and S5C) . Importantly, expression of wildtype or PTEN(C124S) led to reduced Cyclin A 2 -associated CDK2 activity in PC3 cells, suggesting that PTEN(C124S) as well as wild-type PTEN suppresses the G1-S transition, at least in part, through APC-CDH1. Consistent with these data, in vivo xenograft generation with these variants of PC3 cells revealed a significant growth-suppressive activity of PTEN(C124S), in line with the modulation of APC-CDH1 targets ( Figure 6C ). Although expression of PTEN(C124S) led to a significant reduction in the level of late mitotic substrates of APC-CDH1, such as Aurora A, PLK1, and CDC20, the length of mitosis was not significantly shortened, compared to parental PC3 cells ( Figures S5D  and S5E ). Importantly, phosphatase-inactive PTEN(C124S) mutants exhibited comparable activity to wild-type PTEN, enhancing the ubiquitin ligase activity of APC-CDH1 in vitro (as Figure S5 and Figure S6 . p value was determined by Student's t test (*p < 0.01; # p < 0.05).
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measured by Cyclin B ubiquitination) and in vivo (as measured by ubiquitination of Cyclin B and Ets2) ( Figure 6D and Figures  S6A and S6B ). Finally, we found that, like wild-type PTEN, overexpression of phosphatase-inactive PTEN(C124S) resulted in a significant growth suppression accompanied with lower Cyclin A 2 -associated CDK2 activity in immortalized Cdh1 +/+ (or Cdh1 À/À MEFs complemented with human CDH1) but not
Cdh1
À/À cells ( Figure 6E and Figure S6C ).
We then investigated the effects of pharmacological inhibition of PTEN phosphatase activity on APC-CDH1 function. Di-potassium bisperoxo (picolinato) oxovanadate [bpV(Hopic)] inhibits PTEN phosphatase activity (Lai et al., 2007; Rosivatz et al., 2006) . Coimmunoprecipitation analysis revealed that the treatment of DU145 cells with 1 mM bpV(Hopic) had no effects on the formation of APC-CDH1 despite strong activation of AKT ( Figure S6D) . Additionally, the inhibition of PI3-kinase by treatment with 1 mM LY294002 failed to alter the interaction between APC3 and CDH1 or the ubiquitin ligase activity of APC-CDH1 ( Figure S6E ). Taken together, these results demonstrate that PTEN regulates APC-CDH1 in a phosphatase-independent manner.
PTEN Loss but Not Inactivation of Its Phosphatase Activity Results in Hypersensitivity to Pharmacological Inhibition of APC-CDH1 Targets
Inhibition of APC-CDH1 targets, such as PLK1 or Aurora kinases, has been pursued as a therapeutic modality to treat human cancers due to the fact that APC-CDH1 activity is reduced in tumors (Bassermann et al., 2008; Taylor and Peters, 2008) . Indeed, PLK1 inhibitors as well as Aurora A inhibitors are currently being evaluated as anticancer agents (Harrington et al., 2004; Strebhardt and Ullrich, 2006) . In our study we have demonstrated that levels of PLK1 and Aurora A are elevated upon PTEN loss in both asynchronous and synchronized conditions, suggesting that PTEN-deficient tumors might exhibit addiction to these kinases and hence hypersensitivity to their pharmacological inhibition. On the basis of the dispensability of the phosphatase activity of PTEN, we hypothesized that PTEN-deficient tumor cells would be more sensitive to such therapeutic approaches compared to phosphatase-inactive PTEN mutant cells. To test this hypothesis, we first pharmacologically inhibited PLK1 in wild-type and PTEN null cells. Both human and murine Pten null cells were highly sensitive to PLK1 pharmacological inhibition by BI 2536, a PLK1 inhibitor (Figures 7A and 7B and Figures S7A and S7B ; PLK1 inhibition was directly measured by spindle assembly; Figure S7C ). Importantly, the growth inhibitory effect of BI 2536 in PTEN null cells was associated with a profound mitotic arrest followed by apoptosis, as measured by cleavage of Parp and caspase-3 (Cpp32) (Figures 7A, right panel and Figure 7C ). Critically, reconstitution of PTEN null cells with phosphatase-inactive PTEN(C124S) significantly restored the resistance to pharmacological inhibition of PLK1 ( Figures 7B and 7C and Figure S7D) . Similarly, PTEN null cells were hypersensitive to Aurora A inhibition by VX680 (MK0457) (Figures 7D and 7E and Figures S7E and S7F ; Aurora A inhibition was directly measured by histone H3 phosphorylation on Ser10; Figure S7G ). Of note, Aurora A inhibition by VX680 in PTEN null cells induced a robust accumulation of >4 N DNA content-as measured by flow cytometry-and subsequent apoptosis (Figure 7D , right panel and Figure 7F ). Importantly, the sensitivity of phosphatase-inactive PTEN(C124S)-expressing cells to VX680 was similar to that of wild-type PTEN-expressing cells ( Figures 7E and 7F and Figure S7H ). Taken together, these data suggest that PTEN loss but not phosphatase inactivation results in hypersensitivity to pharmacological inhibition of APC-CDH1 targets PLK1 and Aurora A.
DISCUSSION
Our findings allow us to reach a number of relevant conclusions.
First, we have identified a novel mechanism by which PTEN exerts its tumor-suppressive function within the nucleus by regulating the assembly and activity of APC-CDH1. Whereas high concentrations of nuclear PTEN are associated with G0/G1 phase and differentiated cells, lower concentrations of nuclear PTEN level are observed during S phase and in highly proliferating advanced tumors (Gimm et al., 2000; Ginn-Pease and Eng, 2003; Perren et al., 2000) . Furthermore, Pten and Cdh1 are haploinsufficient tumor suppressors in the mouse and their heterozygous loss leads to diverse cancers, including cancers of the prostate and breast (Garcia-Higuera et al., 2008; Salmena et al., 2008) . By contrast, complete acute loss of either tumor suppressor triggers a cellular senescence response (Chen et al., 2005; Li et al., 2008) . In this study, we have demonstrated that Pten-loss-induced senescence is dependent on the Cdh1/Ets2/p16 pathway. On the basis of these data, we propose that PTEN loss elicits a potent senescence response through both phosphatase-dependent (superactivation of a PI3K/mTOR/p53 pathway; Alimonti et al., 2010; Chen et al., 2005) and phosphatase-independent (loss of APC-CDH1 function, unrelated to Arf or p53/p21 pathways) activities, in turn highlighting the complexity of the dose-dependent tumorpromoting and fail-safe cellular responses evoked by PTEN loss ( Figure 7G ).
Second, we find that the novel function of nuclear PTEN presented herein is independent of its phosphatase activity. Cytoplasmic but not nuclear pools of PIP3 are sensitive to catalysis by PTEN, implying a potential role for nuclear PTEN beyond its phosphatase activity (Lindsay et al., 2006) . Indeed, growth-inhibitory effects of nuclear PTEN are likely not mediated directly through the PI3K/AKT pathway (Blanco-Aparicio et al., 2007; Liu et al., 2005) . Given that APC3 is highly phosphorylated on multiple residues in mitosis (Kraft et al., 2003) , one could suspect that PTEN may be a potential phosphatase for APC3. However, in mitotic cells, we did not observe dephosphorylation of APC3 by PTEN neither in vivo nor in vitro (M.S.S. and P.P.P, unpublished data), and in addition, a catalytically inactive form of PTEN is fully functional toward APC. Overall, the phosphataseindependent activity of nuclear PTEN toward APC-CDH1 provides a straightforward explanation for the remnant tumorsuppressive activity associated with the phosphatase-inactive PTEN(C124S) mutation.
Finally, we have demonstrated that PTEN-deficient and PTEN mutant cancer cells are differentially sensitive to pharmacological inhibition of PLK1 and Aurora A. Thus, our study indicates that patients with cancers harboring complete PTEN loss may benefit from pharmacological targeting of the APC-CDH1 pathway, whereas we predict mutant PTEN tumors to be much less sensitive. The APC-CDH1 targets PLK1 and Aurora kinases are overexpressed in human tumors, and this has prognostic and therapeutic potential in cancers (Meraldi et al., 2004; Strebhardt and Ullrich, 2006 (Luo et al., 2009) . By contrast, and in full agreement with our findings, oncogenic PI3K activation does not respond to PLK1 inhibition, suggesting that PTEN-loss-driven hypersensitivity to inhibition of PLK1 and Aurora A is unlikely due to the PI3K/AKT pathway (Luo et al., 2009 ). Hence, our findings provide a rationale for cancer patient stratification based on PTEN loss versus PTEN mutation toward the optimization of targeted therapies. This principle is of great importance given the widespread incidence of these two states of PTEN gene disruption in human cancer. Furthermore, because the functions of PTEN toward PI3K/AKT signaling and the APC-CDH1 pathway are uncoupled, it is tempting to speculate that combinatorial therapy with PLK1/ Aurora kinases and PI3K/mTOR inhibitors may be an effective approach in PTEN null cancers.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies Chemical reagents are from Sigma unless otherwise described. G418, puromycin, and hygromycin, which are used for establishment of stable cell lines, are purchased from Invitrogen. BrdU and anti-BrdU antibody were from BD Biosciences. The PLK1 inhibitor BI 2536 and the Aurora A inhibitor VX680 were from Chemie Tek. All the sources of antibodies used are listed in the Extended Experimental Procedures.
Mass Spectrometry PTEN-deficient PC3 cells transfected with pRK5-Myc-PTEN were subjected to cellular fractionation. The details of nuclear fractionation method are described in the Extended Experimental Procedures. The nuclear extracts were immunoprecipitated with anti-Myc antibody and the PTEN-associated proteins were eluted with Myc peptide. The eluates were resolved by SDS-PAGE on 4%-12% gradient gel (Invitrogen) for silver staining (Pierce). Specific bands were cut out from the gel and subjected to mass-spectrometric peptide sequencing.
Immunoprecipitation and In Vitro Binding Assay
The details of immunoprecipitation and in vitro binding assay are described in the Extended Experimental Procedures.
In Vitro Ubiquitination Assay
The APC/C or PTEN was immunopurified with anti-APC3 (Sigma) or anti-PTEN (Cell Signaling) antibody, respectively, from PC3, DU145, wild-type, and Pten À/À MEFs subjected to nocodazole synchronization and release for 2 or 3 hr. The ubiquitin ligase activity of APC-CDH1 complex was performed as described in detail in the Extended Experimental Procedures.
In Vivo Ubiquitination Assay PC3 cells were cotransfected with pCS2-6Myc-Cyclin B (wild-type or DBM), provided by H. Yu, GFP-PTEN WT or -PTEN K13,289E , and HA-ubiquitin (Ub). Alternatively, cells were transfected with a combination of His-Ub and wildtype or DBM Ets2, provided by P. Zhang (Li et al., 2008) . The details of in vivo ubiquitination assay are described in the Extended Experimental Procedures.
Cell Culture and Flow Cytometry Primary MEFs and PC3 cells complemented with wild-type or phosphataseinactive PTEN(C124S) were established and maintained as described in the Extended Experimental Procedures. The details of cell-cycle analysis by flow cytometry are also described in the Extended Experimental Procedures.
siRNA and shRNA All the sources of siRNA duplexes and shRNA constructs used are described in the Extended Experimental Procedures.
PtdIns(3,4,5)P 3 Phosphatase Assay We purchased diC 8 -PtdIns(3,4,5)P 3 and the Green Reagent from Echelon and Biomol, respectively. Measurement of phosphate released from the substrate was performed according to the manufacturer's instructions and is described in detail in the Extended Experimental Procedures.
In Vitro Kinase Assay
The immunoprecipitates with Cyclin A 2 , Cyclin E 1 , or CDK2 prepared from cell lysates were incubated with histone H1 (Roche) and [g-32 P]ATP (PerkinElmer) for 30 min at room temperature. Reaction mixture was resolved by SDS-PAGE, and then phosphorylated histone H1 was analyzed by SDS-PAGE and autoradiography.
Cell Proliferation and Senescence Assay Typically, cell proliferation and senescence assays were performed as described (Chen et al., 2005) , and the details of methods are described in the Extended Experimental Procedures. For cell proliferation assays with the PLK1 inhibitor BI 2536 Steegmaier et al., 2007) or the Aurora A inhibitor VX680 (Harrington et al., 2004) of BI 2536 or VX680 (Chemie Tek) at a 48 hr period, and then cell growth was measured.
Mouse Xenograft Tumor Model PC3 cells complemented with wild-type or PTEN(C124S) (1 3 10 7 cells per site) in suspension were mixed with equal volumes of matrigel (BD Bioscience) and injected subcutaneously into 6-week-old male nude mice (Charles River laboratory). Measurement of tumor size was performed twice a week, and tumor volume was estimated using the following formula: volume = length 3 width 2 3 0.526.
RNA Isolation and Quantitative Real-Time RT-PCR
Total RNA was isolated with Trizol reagent (Invitrogen) and reverse-transcribed with the Superscript III reverse transcriptase (Invitrogen). Expression of specific mRNAs was determined with the LightCycler (Roche) using the SYBR Green PCR Master Mix (QIAGEN). All the sources of quantitative realtime RT-PCR primers used are listed in the Extended Experimental Procedures.
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